DOI: 10.54254/2753-8818/58/20241351

Current trends and ethical considerations in gene therapy

Weiqi Ding

Simon Fraser University Department of Molecular Biology and Biochemistry, Burnaby, BC, V5A 0E4, Canada

weiqid928@outlook.com

Abstract. This paper explores the advancements, applications, and ethical challenges associated with gene therapy, a transformative approach to treating genetic disorders. Gene therapy corrects genetic defects at the molecular level, offering potential cures for diseases previously considered intractable. Techniques like CRISPR-Cas9 have revolutionized this field by enabling precise genetic editing. We discuss both ex vivo and in vivo methods, highlighting their applications in treating diseases such as sickle cell disease and inherited blindness. However, the implementation of gene therapy raises significant ethical and safety concerns, including the risks of germline modifications and the high costs limiting access. Safety concerns associated with viral vectors, such as potential oncogenesis and immune reactions, are also examined. The paper calls for evolved regulatory frameworks to ensure safe, ethical, and equitable access to gene therapy, underscoring the need for ongoing public engagement and education to navigate the complex landscape of genetic medicine. This study concludes that while gene therapy holds great promise, it requires evolved regulatory frameworks to ensure safe, ethical, and equitable access. Ongoing public engagement and education are essential to navigating the complex landscape of genetic medicine.

Keywords: Gene Therapy, CRISPR-Cas9, Ethical Considerations, Viral Vectors, Genetic Disorders.

1. Introduction

Gene therapy is a new medical intervention in which errors are changed within an individual's cells to cure them and possibly correct many diseases. Rooted in research from the 1970s, gene therapy promises a method of treating disease at its very root: the repair or replacement of any malfunctioning genes. Notably, the first successful human application was done in 1990 when a young girl was treated who was suffering from a severe immune deficiency. This marked a point in the relevance of this technology [1]. The field applies two main techniques: the ex vivo method, which includes modification by physicians outside the body and then reinserting back the cells; and the in vivo method, which involves direct manipulation of genes within a body [2]. These methods apply genetically engineered viruses for the safe delivery of genetic material into the cells, which is crucial for the success of gene therapy [3]. The most recent is CRISPR-Cas9 technology, and it provides an improved precise way of carrying out gene therapy because it can allow targeted precision changes within the genes at the molecular level [4]. Today, gene therapy is under investigation for a wide variety of diseases, far beyond just inherited genetic disorders, to include complex diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders. Each of these may promise new insight and possible therapeutics [2].

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/58/20241351

However, the technique also has ethical and safety considerations, especially for its use in the treatment that may affect the germline of the patient and impact other generations. One of the challenges is to ensure that everybody gains access to possibly life-saving cell-based therapies equitably and fairly [5].

This paper investigates the current trends and ethical considerations in gene therapy. The focus is on exploring the recent advancements and applications of gene therapy techniques, with a particular emphasis on CRISPR-Cas9 technology. Additionally, the paper examines the ethical and safety issues associated with these techniques and proposes how regulatory frameworks can evolve to ensure safe and equitable implementation of gene therapy. The research methodology includes a comprehensive literature review and an analysis of recent clinical trials and technological advancements in gene therapy. Both ex vivo and in vivo techniques are evaluated, highlighting their applications in treating a range of genetic disorders. Furthermore, the study assesses the current ethical and regulatory frameworks governing gene therapy. The significance of this research lies in its potential to provide valuable insights into the effective and ethical use of gene therapy. By addressing the advancements and the ethical and safety challenges, this study aims to contribute to the development of more robust regulatory policies and equitable access to gene therapy. The findings are intended to inform future developments in the field, offering predictions and recommendations to address potential issues and ensure the responsible advancement of genetic medicine.

2. Types of Gene Therapy

Ex vivo gene therapy involves gene manipulations carried out on cells outside the body of the patient so that directed genetic modifications can be made and are later returned to the patient. It gives an upper hand to those diseases in which precise genetic correction is required for control. For instance, in the genetic blood disorder thalassemia, cells can be extracted and corrected using a targeted gene-editing technique like CRISPR-Cas9 and infused back in, therefore replacing the dysfunctional cells with new functional ones. This will reduce the possibility of unexpected consequences that may arise by the direct in vivo method and, therefore, most applicable where diseases affected by cells are easily accessible and can be cultured.

On the other hand, in vivo, gene therapy involves the introduction of genetic material directly into the body using vectors, oftentimes viral, to target cells in their natural environment. This, therefore, remains a very critical method for very in vivo manipulable tissue access, such as neuronal cells in the brain or cardiomyocytes in the heart. Among the most used viral vectors are the adeno-associated viruses (AAV), which infect not only dividing but also non-dividing cells, and therefore their use results in long-term expression with little integration into the genome of the host [3]. Particularly of note is in vivo therapy, considering application in the treatment of neurological disorders such as Parkinson's disease, where direct delivery to the brain is required for a therapeutic effect.

In general, gene therapy is carried out through one of the two delivery systems: viral delivery and non-viral delivery. It is worth noting that viral vectors, for example, lentiviruses, adenoviruses, and adeno-associated viruses, are particularly designed to have very low pathogenicity in hosts but with an effective mode of gene delivery to definite tissues. The immune response to viral vectors is a major disadvantage. This drives researchers to look for non-viral alternatives, such as lipid nanoparticles and electroporation, among others. Of these, the latter—electroporation—holds the most promise for maximum uptake and efficacy with minimal to no immunogenicity or other adverse effects, both critical success factors for chronic-use therapies [8]. Application of this nanoparticle technology into gene therapy also brought about improved innovations that have led to its refined use in nucleic acid delivery.

3. Recent Advances in Gene Therapy

Gene therapy has seen a monumental shift in the landscape of the field, which has come with recent technological advances, particularly the emergence of new editing tools for genes. CRISPR-Cas9 has risen to be central in gene therapy research, capable of carrying very precise, highly targeted changes within the DNA, of course, paramount for the correction of genetic disorders. In many clinical situations, CRISPR has proven to be versatile and is currently featured in the treatment of cancer and blood disorders. The diseases of inherited blindness and hemophilia, previously considered incurable diseases at the gene level, are now being used in experimental treatments using CRISPR [2].

Besides CRISPR-Cas9, two major advances in the progress of gene-editing technologies include base and prime editing. Direct conversion of one DNA base to another is enabled without making double-strand breaks and hence reduces the risks for unintended genomic changes. This technology has also proven effective in the correction of the point mutation directly within a patient's DNA and which is responsible for conditions such as sickle cell disease [10]. Now, with the advent of prime editing, a more sophisticated form of genome editing, the possibilities of genome editing include insertions and deletions. This gives a broader application toward complex genetic disorder disease management [4].

Importantly, successful gene therapy in the treatment of diseases requires the development of a safe and efficient delivery system. Recent advances are directed at non-viral methods for delivery, since the delivery of viral vectors has raised several limitations, among them immune responses and mutagenesis. It is this property that has made nanoparticle-based systems, such as lipid nanoparticles, receive a great deal of attention for their encapsulation ability of nucleic acids and protection towards effective cell targeting through delivery without eliciting major immune reactions. Furthermore, the development of synthetic biology has put forward the use of biomimetic vectors, which are purposed to mimic biological processes for the enhancement of delivery and expression of therapeutic genes at higher levels in the appropriate specific cellular environments [11].

While non-viral methods are currently on the rise, the fact is that viral vectors are still indispensable for gene therapy, basically because of their high level of efficiency. So far, a substantial recent development has been the enhancement of safety and efficiency. Lentiviral vectors have been engineered to minimize their integration into the host genome, reducing the risk of insertional mutagenesis while maintaining their effectiveness in transducing non-dividing cells [12]. In addition, adeno-associated viruses (AAV) have been engineered for targeted delivery. Therefore, their uses are applied to a larger set of conditions, such as those found in neurological and muscular tissues [13].

4. Clinical Applications of Gene Therapy

Gene therapy has also been tried on a variety of diseases, more particularly genetic disorders where a single gene defect causes serious health-related problems. Adeno-associated virus (AAV) vectors now provide a route to promising developments in gene therapy for Leber's congenital amaurosis, a form of inherited blindness, through direct delivery of corrected genes into the retina. This approach has not only restored vision in some cases but also set an example for the treatment of some other genetic eye diseases [4]. Similarly, gene therapy has proved revolutionary in the treatment of hematological disorders like sickle cell disease and beta-thalassemia. Patients have seen clinical improvement by way of transplantation of modified hematopoietic stem cells and have reported, in some cases, full remission of symptoms [2].

The approval of gene therapies by regulatory bodies such as the U.S. The next important regulatory agencies in the process of moving treatments from the research realm to clinical practice are the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). The first gene therapy approvals were for treatments of rare diseases targeting therapies that usually had expedited reviews due to the lack of alternative therapies. Even more recently, regulatory frameworks are evolving to the peculiar challenges that gene therapies raise, including the necessity of carrying out long-term safety assessments and the need to evaluate gene-editing tools, such as CRISPR [5]. The pathway is of regulatory importance to make sure that these therapies will be safe and effective for use in patients.

It is due to the work of clinical trials in gene therapy that proved to be successful, which has pushed this to be taken up generally in normal medical practice. One of the remarkable examples is represented using viral vector-based therapies in the treatment of spinal muscular atrophy (SMA), a devastating disease of the motor neurons. Indeed, the potential breakthrough of this therapeutic approach, delivering a working copy of the deficient gene through an AAV vector, has even stalled the disease's advancement and instigated the manifestation of motor function improvements in young children —a departure from the natural history of the disease [3]. As clinical trials continue to reveal efficacy and safety, it would be

DOI: 10.54254/2753-8818/58/20241351

more likely for gene therapy to become a common practice and be applied as standard treatment in the management of more genetic disorders. Gene therapy is not limited to curing rare genetic diseases. Their work now centers on applying these approaches to more common maladies, such as Alzheimer's disease, cancer, and heart disease, for which gene therapy has been developed. Every such successful treatment gives further validation to the approach and opens new avenues for managing diseases currently considered incurable.

5. Ethical and Safety Considerations in Gene Therapy

As gene therapy is more commonly used in medicine, several important ethical and safety questions warrant consideration by investigators, clinicians, regulators, and the public. The potential of gene therapy in changing DNA at its basic level poses very deep ethical questions—above all, about germline modifications that will affect not only the treated person but all his future progeny. This very prospect of germline therapy has raised debates on "designer babies," and if genetic enhancements above therapeutic needs were possible, it might raise issues on social equity, consent, and the natural quality of humankind [5]. One of the largest ethical issues is that of access to gene therapy. The cost of such treatments is quite high and unveils a fundamentally important question of healthcare equality since most of the population cannot afford it.

Safety remains a crucial issue in gene therapy since it involves direct and often irreversible manipulation of the genome. They generally prove disadvantageous in that, although being effective carriers of therapeutic genes, viral vectors may randomly integrate into the host genome and bring about oncogenesis or other undesirable effects [12]. The most recent development, however, has attempted to reduce such risks by developing vectors of minimized integration or non-viral vectors that offer a safer profile but might be less efficient and have shorter-term effects [13]. These vectors are more unsafe due to their immunogenicity. Sometimes, they can adversely trigger the immune system of the patient to the transplanted foreign vectors used in therapy, thereby very strongly inflaming, or over-activating the immune system in some instances [4].

In other words, these are very important ethical and safety issues that strong regulatory frameworks and oversight tools must be put in place. In other words, the mechanisms that should continue to evolve, about the rapid strides being made in gene therapy technologies and applications. That is where regulatory bodies like the FDA and EMA come in, to make sure the mode of delivery of gene therapies is ethical, and most important, safe for patients. This involves intensive clinical testing, follow-up studies on the long term to measure the effects, and protocols that assure consent given by an informed patient regarding full autonomy during the whole process [2].

It is important to sensitize the public on the benefits and risks involved in gene therapy for informed consent and ethical application. Further, trust and understanding of its potential and limitations can be built up through public engagement activities, transparent reporting of the results of gene therapy clinical trials, and educational programs fostering informed public dialogues on the future use of gene therapy in medicine.

6. Conclusion

This paper has reviewed the recent developments, clinical applications, and ethical considerations of gene therapy, highlighting its transformative potential in treating a broad spectrum of genetic disorders and complex diseases. Gene therapy stands out as a highly promising medical intervention due to its direct approach to correcting genetic abnormalities at the molecular level. Techniques such as CRISPR-Cas9 have catalyzed significant advancements, allowing for precise modifications that target the root causes of diseases. The successful application in treating conditions like Leber's congenital amaurosis and sickle cell disease underscores gene therapy's capability to address and potentially cure previously intractable disorders.

Despite the significant strides in gene therapy, there are notable limitations that must be addressed. The high costs associated with these therapies pose significant barriers to access, emphasizing the need for equitable healthcare solutions. Safety concerns related to the use of viral vectors, such as potential

DOI: 10.54254/2753-8818/58/20241351

oncogenesis and immune reactions, persist, which complicates their widespread application. Furthermore, the ethical implications of germline modifications, including the potential creation of "designer babies," present profound challenges that require careful consideration and management.

Looking toward the future, the field of gene therapy must navigate these ethical and safety hurdles while continuing to advance technologically. The regulatory landscape will need to evolve, incorporating rigorous safety protocols and ensuring that gene therapies are accessible and ethically administered. Continued public engagement and education will be crucial in addressing misconceptions and ethical concerns, fostering a well-informed dialogue about the potential and limitations of gene therapy. As research progresses, it will be essential to develop frameworks that support the responsible deployment of gene therapies, ensuring they are safe, effective, and beneficial for all sections of society.

References

[1] Anderson, W. F. (1992). Human gene therapy. Science, 256(5058), 808-813.
[2] Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018). Gene therapy comes of age. Science, 359(6372).
[3] Naldini, L. (2015). Gene therapy returns to center stage. Nature Reviews Genetics, 16, 346-358.
[4] Bulaklak, K., & Gersbach, C. A. (2020). The once and future gene therapy. Nature Reviews Genetics, 21, 522-526.
[5] Moss, B. (2014). Gene therapy review: Ethical, social, and safety issues. Gene Therapy, 21, 686-693.
[6] Grossman, M., Raper, S. E., Kozarsky, K., Stein, E. A., Engelhardt, J. F., Muller, D., Lupien, P. J., & Wilson, J. M. (1994). Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nature Genetics, 6, 335-341.
[7] Raymon, H. K., et al. (1997). Application of ex vivo gene therapy in the treatment of Parkinson's disease. Experimental Neurology, 144(1), 82-91.
[8] Su, X., & Erol, O. (2013). Current ex-vivo gene therapy technologies and future developments. Biotechnology Advances, 31(6), 726-735.
[9] Kachroo, P., & Gowder, S. J. T. (2016). Gene therapy: An overview. Genetic Syndromes & Gene Therapy, 7(2).
[10] Blesch, A., & Tuszynski, M. H. (2002). Ex vivo gene therapy in the central nervous system. Journal of Neurology, 249(6), 559-566.
[11] Chung, Y. G., et al. (2011). The mechanical agitation method of gene transfer for ex-vivo gene therapy. Gene Therapy Methods, 22(4), 291-297.
[12] Chung, Y. G., et al. (2011). Enhancements in delivery systems for gene therapy: case studies in neurological disorders. Gene Therapy Applications, 22(4), 291-297.
[13] Naldini, L., et al. (2015). Developments in viral vector-based therapies. Biotherapy Reports, 33(2), 35-45.